Vidarabine, 98%, an antiviral drug which is active against herpes simplex and varicella zoster viruses 阿糖腺苷

CAS 5536-17-4 MFCD05536174

化学结构图

5536-17-4
SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

化学属性

Mol. Weight267.24
Mol. FormulaC10H13N5O4
Melting Point260°C
Boiling Point410.43 °C at 760 mmHg

别名和识别编码

Chemical Name Translation阿糖腺苷
Wiswesser Line NotationT56 BN DN FN HNJ IZ D- ET5OTJ B1Q CQ DQ *D-ARABINO
Chemical NameVidarabine, 98%, an antiviral drug which is active against herpes simplex and varicella zoster viruses
Synonym Vidarabine {LY} Vidarabine {} {LY} Vidarabine {} {} {LY} Vidarabine {} {} {} {LY} Vidarabine {} {} {} {} {LY} Vidarabine {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidarabine {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Vidara
Beilstein Registry Number624881
CAS Number5536-17-4
PubChem Substance ID21704
EC Number226-893-9
MDL NumberMFCD00065471
Reaxys-RN93029
Merck Number9976
LabNetwork Molecule IDLN00219929
InChIInChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1
Canonical SMILESOC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SNA} Antibiotics A to Z, Antibiotics A-F, Antiviral, Chemical Structure Class, Inhibits an Enzyme, Interferes with DNA Synthesis, Mechanism of Action, Nucleosides, Spectrum of Activity, 抗生素, 生化试剂

安全信息

RTECSAU6200000
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : >5 gm/kg
TOXIC EFFECTS :
   Liver - other changes
REFERENCE :
   ANYAA9 Annals of the New York Academy of Sciences.  (New York Academy of
   Sciences, 2 E. 63rd St., New York, NY 10021)  V.1-    1877-
   Volume(issue)/page/year: 284,6,1977

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 8914 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   IYKEDH Iyakuhin Kenkyu.  Study of Medical Supplies.  (Nippon Koteisho
   Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan)  V.1- 1970- 
   Volume(issue)/page/year: 15,688,1984

{

TYPE OF TEST            : LD50 - Le

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Human
DOSE/DURATION           : 2 mg/kg
TOXIC EFFECTS :
   Brain and Coverings - changes in surface EEG
   Behavioral - toxic psychosis
   Behavioral - ataxia
REFERENCE :
   JIDIAQ Journal of Infectious Diseases.  (Univ. of Chicago Press, Journals
   Div., POB 37005, Chicago, IL 60637)  V.1-    1904- Volume(issue)/page/year:
   134,75,1976

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Human
DOSE/DURATION           : 300 ug/kg
TOXIC EFFECTS :
   Behavioral - anorexia (human)
   Gastrointestinal - hypermotility, diarrhea
   Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
   JIDIAQ Journal of Infectious Diseases.  (Univ. of Chicago Press, Journals
   Div., POB 37005, Chicago, IL 60637)  V.1-    1904- Volume(issue)/page/year:
   133,A192,1976

TYPE OF TEST            : Cytogenetic analysis
ROUTE OF EXPOSURE       : Intravenous
TEST SYSTEM             : Human
DOSE/DURATION           : 2500 ug/L
REFERENCE :
   DABBBA Dissertation Abstracts International, B: The Sciences and
   Engineering.  (University Microfilms International, 300 N. Zeeb Rd., Ann
   Arbor, MI 48106)  V.30-    1969-  Volume(issue)/page/year: 35,4518,1975

TYPE OF TEST            : DNA inhibition
TEST SYSTEM             : Mammal - species unspecified Cells - not otherwise
                          specified
DOSE/DURATION           : 10 umol/L
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 120,139,1983

TYPE OF TEST            : Mutation test systems - not otherwise specified
TEST SYSTEM             : Rodent - mouse Leukocyte
DOSE/DURATION           : 251 mg/L
REFERENCE :
   BCPCA6 Biochemical Pharmacology.  (Pergamon Press Inc., Maxwell House,
   Fairview Park, Elmsford, NY 10523)  V.1-

{

TYPE OF TEST            : Cytogenetic analysis
TEST SYSTEM             : Mammal - species unspecified Cells - not otherwise
                          specified
DOSE/DURATION           : 1 mmol/L
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 120,139,1983

TYPE OF TEST            : Mutation test systems - not otherwise specified
TEST SYSTEM             : Human Leukocyte
DOSE/DURATION           : 100 umol/L
REFERENCE :
   CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut

TYPE OF TEST            : Mutation in mammalian somatic cells
TEST SYSTEM             : Rodent - hamster Ovary
DOSE/DURATION           : 100 umol/L
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amste

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 2 gm/kg
SEX/DURATION            : female 6-15 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - craniofacial
   (including nose and tongue)
   Reproductive - Specific Developmental Abnormalities - urogenital system
   Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
   TJADAB Teratology, The International Journal of Abnormal Development. (Alan
   R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1968-
   Volume(issue)/page/year: 15,231,1977

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 2 gm/kg
SEX/DURATION            : female 6-15 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
   resorbed implants per total number of implants)
   Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
   e.g., stunted fetus)
REFERENCE :
   TJADAB Teratology, The International Journal of Abnormal Development. (Alan
   R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1968-
   Volume(issue)/page/year: 15,231,1977

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 2500 mg/kg
SEX/DURATION            : female 6-15 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - Central Nervous System
   Reproductive - Specific Developmental Abnormalities - eye/ear
   Reproductive - Specific Developmental Abnormalities - body wall
REFERENCE :
   TJADAB Teratology, The International Journal of Abnorma

GHS Symbol
Hazard Codes Xn
Hazard statements
  • H361 Suspected of damaging fertility or the unborn child 怀疑对生育能力或未出生婴儿造成伤害
Risk Statements
  • R63 Possible risk of harm to the unborn child 可能危害未出生婴儿
WGK Germany3
Safety Statements
  • S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套;
Precautionary statements
  • P281 Use personal protective equipment as required. 使用所需的个人防护装备。
Signal word Warning
Storage condition 2-8°C {LY} 2-8°C {} {LY} 2-8°C {} {} {LY} 2-8°C {} {} {} {LY} 2-8°C {} {} {} {} {LY} 2-8°C {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {

系列性分类


相关产品推荐